Novo Nordisk (NVO) stock: return calculator
Novo Nordisk (NVO) shares, the Danish pharma company behind Ozempic and Wegovy, listed in New York.
Updated
- Type
- Stocks
- Market
- NYSE
- Currency
- USD
- Sector
- Healthcare
- Data range
- 2016-09 – 2026-08 · 10 years
- Source
- Yahoo Finance
US$1,000 invested 9 years ago would be worth today
US$2,426
+142.6% total return
Try your own values in the calculators below.
Return calculator
Pick an amount and a period to see what an investment in Novo Nordisk (NVO) would be worth today. By default we include reinvested dividends (total return).
Lump sum
What a one-off investment would be worth today.
Monthly investing (DCA)
What investing the same amount every month would be worth.
Estimate before taxes, fees and currency-conversion costs. Past performance does not guarantee future returns.
Investment growth
Performance
Data for the last 10 years · 2016-09 → 2026-08
Comparison with the market
US$1,000 invested vs S&P 500 ETF (SPY):
- Novo Nordisk (NVO)
- US$2,863
- S&P 500 ETF (SPY)
- US$3,992
Novo Nordisk (NVO) trailed S&P 500 ETF (SPY) over this period.
Risk & drawdowns
The largest peak-to-trough drop in the window was -72.9%. An investor who bought near the prior peak would have seen the investment fall significantly before recovering.
Scenarios
Illustrative results based on the available data.
US$1,000 5 years ago
US$1,057
lump sum, +5.7% return
US$100/mo for 5 years
US$4,732
invested US$6,100
If it repeats +11.2%/yr for 10 years
US$2,888
projection from US$1,000 (hypothetical)
About Novo Nordisk (NVO)
Novo Nordisk is a Danish pharmaceutical company with over a century of history, the world leader in diabetes treatment and, more recently, in obesity. The drugs Ozempic and Wegovy, both based on semaglutide, turned it into one of Europe's most valuable companies and account for a very large share of revenue.
The shares trade in New York under the ticker NVO as an ADR (a certificate representing shares in the Danish company), with the primary listing in Copenhagen. After years of steep gains, the stock corrected sharply between 2025 and 2026, as direct competition arrived in obesity, above all from America's Eli Lilly, trial results disappointed and pricing pressure built in the United States.
Related calculators
Other assets
Frequently asked questions
How much did Novo Nordisk (NVO) stock return over the last 10 years?
Do these calculations include dividends?
Do they include taxes or fees?
What currency are the values in?
Does past performance predict the future?
Sources & methodology
Prices: Yahoo Finance. Monthly series, total return (dividends reinvested). Data through 2026-08-10.
Total return assumes dividends are reinvested; you can turn that off to see price-only appreciation. Values are estimates before taxes, fees and currency-conversion costs.
Page generated and reviewed by the Calculadora Capital editorial team. Last updated 2026-08-10.